Jacek Gniot
A5031068867- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Cardiac electrophysiology and arrhythmias
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Diabetes Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrest and Resuscitation
- Cardiovascular Syncope and Autonomic Disorders
- Acute Ischemic Stroke Management
- Cardiac and Coronary Surgery Techniques
- Cardiac Imaging and Diagnostics
- Vitamin K Research Studies
- Cardiac Structural Anomalies and Repair
- Spinal Hematomas and Complications
- Lipoproteins and Cardiovascular Health
- Antioxidant Activity and Oxidative Stress
- Cardiac Fibrosis and Remodeling
- Vitamin C and Antioxidants Research
- Cardiovascular Issues in Pregnancy
- Cardiac pacing and defibrillation studies
- Case Reports on Hematomas
- Spinal Dysraphism and Malformations
National Veterinary Research Institute
2005
To assess tolerability and optimal time point for initiation of sacubitril/valsartan in patients stabilised after acute heart failure (AHF).TRANSITION was a randomised, multicentre, open-label study comparing two treatment modalities sacubitril/valsartan. Patients aged ≥ 18 years, hospitalised AHF were stratified according to pre-admission use renin-angiotensin-aldosterone system inhibitors randomised (n = 1002) stabilisation initiate either 12-h pre-discharge or between Days 1-14...
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects empagliflozin exercise patient-reported outcomes in heart failure (HF) reduced preserved ejection fraction (EF), without type 2 diabetes (T2D), reporting, for first time, sodium-glucose co-transporter-2 inhibition EF (HFpEF).HF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or (>40%, 315, EMPERIAL-Preserved), T2D, were randomized to 10 mg placebo 12 weeks....
This study examined the effects of sacubitril/valsartan on N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels and determined patient characteristics associated with favorable NT-proBNP reduction response. reflect cardiac wall stress predict event risk in patients acute decompensated heart failure (ADHF). Post-hoc analysis TRANSITION (Comparison Pre- Post-discharge Initiation Sacubitril/Valsartan Therapy HFrEF Patients After an Acute Decompensation Event) study, including stabilized...